How biosimilars are grabbing market share among HCPs. It’s a widely held belief that biosimilars, or “generic” versions of biologics (medicines produced from living organisms), hold great promise to reduce healthcare costs worldwide. Because biosimilars require less money to develop, they typically sell at a discount to... read more →